Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man CY, Urbaityte R, Brandon DJ, Underwood M, Pappa KA, Curtis L, Smith KY, Gartland M, Aboud M, van Wyk J, Wynne B.
Cahn P, et al. Among authors: ortiz r.
AIDS. 2022 Jan 1;36(1):39-48. doi: 10.1097/QAD.0000000000003070.
AIDS. 2022.
PMID: 34534138
Free PMC article.
Clinical Trial.